COVID-19 Impact on Global Recombinant Vaccines Market: Ken Research

0


Product Overview

Using recombinant DNA technology or genetic engineering to prevent lethal diseases in humans and animals, recombinant vaccines are made. A recombinant vaccine is a biological preparation that provides the active immunity gained against a specific disease, whereas the vaccinated individual produces antibodies against the protein antigen that, upon attack from the pathogenic microorganism, prevent a person from contracting the disease. These vaccines work on disease immune response and have preventive measures against diseases caused by different bacteria and viruses. Compared with traditional vaccines, these vaccines are much more advanced and effective in preventing diseases such as malaria, typhoid, and human papillomavirus (HPV).

Market Highlights

Global Recombinant Vaccines Market

                                       Global Recombinant Vaccines Market

Global Recombinant Vaccines Market size was registered at USD 0.94 billion in 2019 and is estimated to reach USD 2.04 billion by 2030, registering a CAGR of 7.16% from 2020 to 2030. The global demand for recombinant vaccines is largely driven by an increase in advanced technological products, a rising number of regulatory approvals, a high prevalence of infectious diseases, and an increasing penetration of key players in the market. Also, rising healthcare awareness, favorable reimbursement policies, growing innovation in drug and vaccine research and development, as well as increasing the average income of individuals, are driving the market growth.

Global Recombinant Vaccines Market: Segments

Recombinant Vaccines Market is segmented based on patient type, technology, and region.

By Patient Type (in %), Recombinant Vaccines Market, 2019

The pediatric patient’s segment is anticipated to register XX% of the market share during the forecasted period.

By patient type, the market can be segmented into pediatric and adult patients. The largest share of the global vaccine market was in the pediatric patient’s group. This can be due to the growing government initiatives for immunization and the rising prevalence of diseases.

By Technology (in %), Recombinant Vaccines Market, 2019

The conjugate vaccine segment accounted for XX% of the nation’s volume in 2019

The technology segment can be classified into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The largest share of the vaccine market was in the conjugate vaccine category. Increasing government funding and increasing company involvement in conjugate vaccine production can be due to the significant share of this category.

Recombinant Vaccines Market Dynamics:

Increasing research and development and government approvals to increase the market growth

Global demand for recombinant vaccines is largely driven by an increase in advanced technological products, a rising number of regulatory approvals, a high prevalence of infectious diseases, and an increasing penetration of key players in the market. Also, rising healthcare awareness, favorable reimbursement policies, growing innovation in drug and vaccine research and development, as well as increasing the average income of individuals, are driving the market growth.

Request for Sample Report: – https://www.kenresearch.com/sample-report.php?Frmdetails=Mzk5NjI5

High vaccine costs and side effects of treatment to hinder the market growth

Market growth is likely to be impeded by factors such as high vaccine costs, risks associated with live attenuated vaccines, as well as sore throat irritability after vaccine administration, and strict regulatory policies. The lack of adequate health care facilities, as well as information in middle-income countries about pathogen-related diseases, is a major challenge to market development.

Global Recombinant Vaccines Market: Regions

In terms of value and volume, North America accounted for XX% of total market volume share in 2019

The largest share of the vaccine market in North America was attributed to the high prevalence of infectious diseases and increased spending by government and non-governmental vaccine production organizations. On the other hand, the demand at APAC is expected to report the highest growth over the forecast period. Factors such as growing healthcare spending and rising disposable income, government policies, and the presence of a large patient population are driving growth in the APAC region’s vaccine sector.

The region segment can be further divided into five major types including North America, Latin America, Europe, APAC, and MENA.

Global Recombinant Vaccines Market is further segmented by region into:

North America Market Size, Share, Trends, Opportunities-o-Y Growth, CAGR – United States and Canada

Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America

Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe

APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC

MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Global Recombinant Vaccines Market: Impact of COVID-19

The global pandemic COVID-19 has become global stress, not just for human lives, but also for industries across different industry verticals. The COVID-19 disease has infected several million people globally, with an increasing number of active cases daily, the duration of the pandemic is still difficult to predict. The epidemic of COVID-19 has had an enormous effect on countries around the world, putting an economic burden on the population. However, the market for vaccines has been growing worldwide due to their efficacy against deadly infections. Increased R&D leading to the production of a possible COVID-19 recombinant vaccine is projected to increase the market potential in the year’s forecast. Therefore, due to the launch of many coronaviruses’ positive patients, the market is expected to experience positive growth during the forecast period.

Recombinant Vaccines Market: Competitive landscape

New technological advancements in the Recombinant Vaccines Market as well as large production output of the product by key players are likely to increase the market growth. In this segment, the pharmaceutical companies have dramatically strengthened their supply chain management, enhanced their R&D capabilities, and invested more in their production management and quality control.

Global Recombinant Vaccines Market: Key players

Johnson and Johnson

Company Overview

Business Strategy

Key Product Offerings

Financial Performance

Key Performance Indicators

Risk Analysis

Recent Development

Regional Presence

SWOT Analysis

Abiomed

Emergent Bio Solutions, Inc.

GlaxoSmithKline

Sanofi Pasteur SA

Serum Institute of India Pvt. Ltd

Mitsubishi Tanabe Pharma Corporation

Daiichi Sankyo

Pfizer, Inc.

Other prominent players

Global Recombinant Vaccines Market report also contains analysis on:

Recombinant Vaccines Market segments: –

By Type:

Pediatric

Adult Patients

By Technology:

Conjugate vaccines

Inactivated and subunit vaccines

 live attenuated vaccines

Recombinant vaccines

Toxoid Vaccines

Recombinant Vaccines Market dynamics

Recombinant Vaccines Market size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies Involved in the Market

Value Chain of the Market

Market Drivers and Restraints

For More Info on the Research Report, Click on the below link: –

Global Recombinant Vaccines Market Growth Rate

Related Report by Ken Research: –

Biologics Outsourcing Market by Product (Antibody, Recombinant Protein, Vaccines, and Others), by Type (Kits & Reagents and Instruments), by Sources (Microbial, Mammalian and Others) and for Applications (Vaccine & Therapeutics Development, Blood & Blood Related Products Testing, Cellular and Gene Therapy, Tissue and Tissue Related Products Testing, and Stem Cell Research): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

Contact Us: –
Ken Research
Ankur Gupta, Head Marketing & Communications
Support@kenresearch.com
+91-9015378249

Follow Us

LinkedIn | Facebook | Twitter | YouTube

Share.